Health Care · Surgical & Medical Instruments & Apparatus

UTMD UTAH MEDICAL PRODUCTS INC SEC Filings & Insider Trading Activity 2026

company
CIK 706698133 filings
Russell 2000

UTMD at a glance

UTAH MEDICAL PRODUCTS INC (UTMD, SEC CIK 706698) filed its latest 10-K annual report on March 27, 2026, a 10-Q quarterly report on November 13, 2026, an 8-K current report on November 3, 2026 and Form 4 insider filings as recently as October 29, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), UTAH MEDICAL PRODUCTS INC (UTMD) reported revenue of $38.5 million (down 5.8% from FY2024) and net income of $11.3 million. Diluted EPS was $3.48.
  • As of September 30, 2026, 23 institutional investment managers tracked by SignalX reported holding UTAH MEDICAL PRODUCTS INC (UTMD) shares worth $74.0 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by CORNWELL KEVIN L on October 29, 2026 of 1,000 shares at $66.75 per share.
  • In the last 90 days, UTMD insiders reported 1 open-market purchase ($67K) and 0 open-market sales ($0) on Form 4, a net purchase of $67K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$38.5M
−5.8% vs prior year
Insiders · 90 days
1 buy · 0 sells
Net +$67K
13F holders
23 funds
$74.0M · −1 vs prior quarter
Latest 8-K
Nov 3, 2026
Item 8.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes disclosed from the December 31, 2025 Form 10-K risk factors
  • Unknown or currently immaterial risks could materially adversely affect business, financial condition, or operating results

Management Discussion & Analysis

  • 3Q revenue $8.621M, down 12.1% YoY from $9.812M, primarily lost PendoTECH and China distributor sales
  • Operating margin 32.4% vs 26.6% YoY, gross margin 56.1% vs 57.1%
  • Best category Blood Pressure Monitoring and Accessories $1.927M, up from $1.643M; worst Neonatal $1.667M, down from $2.176M
  • Cash and investments $85.2M vs $85.8M year-end, with $3.0M dividends, $0.9M repurchases and $5.0M Orion acquisition
  • 2026 revenue outlook down 7%-8%, EPS near $3.60 vs $3.48, with slower biopharma replacement sales and Filshie declines as headwinds

AI summary of the UTMD 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 3, 2026Full analysis →

Item 8.01: Other Events

  • Quarterly cash dividend increased to $0.315 per share
  • Payment scheduled for January 5, 2027

Item 99.1:

  • Filing contains only the 8-K signature block, with no substantive operating, financial, or strategic disclosure
  • CEO Kevin L. Cornwell signed the report on November 3, 2026

Item EX-99.1: Item EX-99.1

  • Quarterly dividend increased 1.6% to $0.315 per share
  • Payment scheduled January 5, 2027, for shareholders of record December 17, 2026
Filed Oct 22, 2026Full analysis →

Item 99.1:

  • Press release covers fiscal 2026 and nine months ended September 30, 2026
  • Forward-looking statements address 2026 and beyond, relevant to expectations but subject to execution risks

Item EX-99.1: Item EX-99.1

  • 3Q revenue $8.621M, down 12.1%, reflecting lost PendoTECH and China distributor sales plus weaker Filshie demand
  • 3Q net income $2.787M, up 5.9%, and diluted EPS $0.876, up 6.8%, supported by lower litigation, amortization and taxes

Item 2.02: Results of Operations and Financial Condition

  • Exhibit 99.1 covers UTMD results for the three and nine months ended September 30, 2026
  • Press release dated October 22, 2026 includes forward-looking statements for 2026 and beyond
Filed Aug 31, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Femcare Ltd acquired all common shares of UK-based Orion Medical Supplies Ltd
  • Transaction expands Utah Medical Products’ wholly owned subsidiary operations in the United Kingdom

Item EX-99.1: Item EX-99.1

  • Femcare acquired all Orion Medical Supplies shares, expanding UTMD’s UK and European medical-device distribution
  • Purchase price £3.6 million, funded from cash reserves

AI summaries of UTMD 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for UTMD

Don't miss the next UTMD filing

  • Alerts as it files. A push when UTMD files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut UTMD, by share count.
  • Ask anything. An AI agent that reads every UTMD filing and answers with sources.

UTMD alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
CORNWELL KEVIN LBuyOct 29, 2026$66.75
RICHINS PAUL OGJun 29, 2026$73.07
Koopman BrianGMay 28, 2026$66.27
Koopman BrianAOct 31, 2025-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$40.9M$38.5M
Gross Profit-$24.1M$22.0M
Operating Income-$13.6M$11.4M
Net Income-$13.9M$11.3M
Gross Margin-59.0%57.1%
Op. Margin-33.2%29.6%
Net Margin-33.9%29.3%
Balance Sheet
Total Assets$135.5M$122.5M$122.5M
Equity$128.3M$117.4M$119.3M
ROE-11.8%9.5%
Per Share
EPS-$3.96$3.48
Cash Flow
Operating CF-$14.8M$14.7M
CapEx-$230K$371K

Source: XBRL data in UTAH MEDICAL PRODUCTS INC (UTMD)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate UTMD share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
UTMD shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202623$74.0M
Q2 202624$71.3M
Q1 202625$62.1M
Q4 202524$58.6M
Q3 202523$67.6M
Q2 202524$63.4M
Q1 202521$55.5M
Q4 202416$57.3M
Position changes: Q2 2026 → Q3 2026
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 180 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

UTMD filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 13, 2026Analysis
8-KNov 3, 2026Analysis-
4Oct 29, 2026--
8-KOct 22, 2026Analysis-
8-KAug 31, 2026Analysis-
10-QAug 12, 2026Analysis
8-KJul 23, 2026Analysis-
4Jul 1, 2026--
4May 29, 2026-
10-QMay 12, 2026Analysis
8-KMay 4, 2026Analysis-
8-KApr 23, 2026Analysis-
10-KMar 27, 2026-
8-KJan 29, 2026-
4Nov 25, 2025-
10-QNov 14, 2025Analysis
10-QAug 12, 2025-
SC 13GJul 17, 2025-
10-QMay 15, 2025-
SC 13GMay 14, 2025-
10-KMar 26, 2025-
10-QNov 12, 2024-
SC 13GOct 31, 2024-
10-QAug 9, 2024-
10-QMay 10, 2024-

Related Health Care companies

All Health Care →

UTMD SEC filings: frequently asked questions

Are UTMD insiders buying or selling?

In the last 90 days, UTAH MEDICAL PRODUCTS INC (UTMD) officers, directors and 10% owners reported 1 open-market purchase worth $66,750 by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold UTMD stock?

As of September 30, 2026, the largest UTAH MEDICAL PRODUCTS INC (UTMD) holders among the 13F filers tracked by SignalX were Dimensional Fund Advisors ($15.1 million), BlackRock ($14.6 million), Renaissance Technologies LLC ($12.4 million), Vanguard Capital Management LLC ($10.1 million), State Street Corp ($4.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was UTMD's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), UTAH MEDICAL PRODUCTS INC (UTMD) reported revenue of $38.5 million (down 5.8% from FY2024) and net income of $11.3 million. Diluted EPS was $3.48. The figures come from the XBRL data in the 10-K.

What did UTMD report in its latest 8-K?

UTAH MEDICAL PRODUCTS INC (UTMD) filed an 8-K on November 3, 2026 reporting Item 8.01 (Other Events). Quarterly cash dividend increased to $0.315 per share.

What are the latest UTMD SEC filings?

UTAH MEDICAL PRODUCTS INC (UTMD) filed its latest 10-K annual report on March 27, 2026, a 10-Q quarterly report on November 13, 2026, an 8-K current report on November 3, 2026 and a Form 4 insider filing on October 29, 2026.

What is UTMD's SEC CIK number?

UTAH MEDICAL PRODUCTS INC (UTMD)'s SEC Central Index Key (CIK) is 706698. EDGAR lists every UTMD filing under that number.

Ask anything about UTMD

The research agent reads UTMD's filings, financials, insider trades and 13F holders, then answers with sources.